TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Allogene Therapeutics
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis

Allogene Therapeutics won a favorable arbitration ruling with Cellectis, reconfirming full development and commercial control of cemacabtagene ansegedleucel (cema-cel) in the US, EU, and UK, with a path to acquire full global rights by 2026.

Insights
TpC   neutral

Venue provider for the Pause With Purdue event with no significant active role


ALLO   positive

Won arbitration case, secured full control of cema-cel product, and cleared path for global commercialization rights